NR3C1 and neoplasm: Thus, treatment with the clinical GR antagonist mifepristone can sensitize ICB-refractory PDAC to anti-CTLA-4 and anti-PD-l antibodies, resulting in not only substantial tumor growth inhibition but also significant survival benefit.